Vio-Fung

Serious Warnings

• Black Box Warning: As griseofulvin does not carry an official FDA Black Box Warning, the following section outlines 'Serious Warnings' that warrant significant clinical attention and careful patient management during therapy. **Serious Warnings: Griseofulvin (Example brand: Grivin)** * **Potential for Hepatotoxicity:** Griseofulvin carries a risk of significant hepatotoxicity, including dose-related elevations in liver enzymes and, in rare instances, severe idiosyncratic liver damage, cholestasis, or hepatic necrosis. Patients must undergo baseline liver function testing (LFTs) prior to initiating therapy and be monitored regularly throughout prolonged treatment, especially those with pre-existing hepatic conditions. Griseofulvin should be discontinued immediately if clinically significant liver dysfunction, persistent nausea, vomiting, abdominal pain, dark urine, jaundice, or other signs of liver injury develop. * **Teratogenic Potential and Reproductive Risk:** Griseofulvin is contraindicated in pregnant women due to its established teratogenic effects in animal studies and potential for serious fetal harm in humans. Women of childbearing potential are required to use highly effective contraception during griseofulvin treatment and for at least one month after the final dose. Men should also consider contraceptive measures during and for a period after treatment due to potential effects on spermatogenesis, although human data is limited. * **Hematologic Abnormalities:** Leukopenia (decreased white blood cell count) and neutropenia have been reported during griseofulvin therapy. Complete blood counts (CBCs) should be obtained before starting treatment and monitored periodically, particularly during long-term administration, to detect and manage any clinically significant hematologic changes. Drug discontinuation may be necessary if abnormalities persist or worsen. * **Severe Photosensitivity Reactions:** Patients receiving griseofulvin are at increased risk for severe photosensitivity reactions, including exaggerated sunburn, blistering, and rash, upon exposure to ultraviolet light (from natural sunlight or artificial sources like tanning beds). Strict sun avoidance and the consistent use of protective clothing, wide-brimmed hats, and high-SPF broad-spectrum sunscreen are imperative throughout the entire course of therapy. * **Severe Cutaneous Adverse Reactions (SCARs):** Although rare, severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported with griseofulvin. Patients should be advised to seek immediate medical attention if they develop widespread rash, blistering, mucosal lesions (mouth, eyes, genitals), or fever, as these are medical emergencies. * **Exacerbation of Lupus Erythematosus:** Griseofulvin may precipitate or exacerbate symptoms of lupus erythematosus and related autoimmune syndromes. Caution is advised in patients with a history of such disorders, and vigilant monitoring for signs and symptoms of disease exacerbation is crucial.
• Careful consideration and comprehensive monitoring are essential during griseofulvin therapy due to several significant warnings and potential for serious adverse events.
• **Hepatotoxicity:** Griseofulvin has the potential for dose-related and idiosyncratic hepatotoxicity.
• Baseline liver function tests (LFTs) should be obtained prior to initiating therapy and monitored periodically (e.
• g.
• , monthly for the first few months, then quarterly) during prolonged treatment, especially in patients with pre-existing liver impairment.
• Discontinuation is warranted if LFTs become significantly elevated (e.
• g.
• , >3 times the upper limit of normal) or if clinical signs and symptoms of liver dysfunction (e.
• g.
• , persistent nausea, vomiting, abdominal pain, dark urine, jaundice) develop.
• **Hematologic Effects:** Leukopenia and neutropenia have been observed with griseofulvin therapy.
• Complete blood counts (CBCs) should be performed at baseline and monitored regularly, particularly during long-term therapy, to detect and manage potential hematologic abnormalities.
• If blood dyscrasias are identified, the drug should be discontinued.
• **Photosensitivity:** Patients should be stringently advised about the risk of severe photosensitivity reactions, including exaggerated sunburn, blistering, and rash, upon exposure to ultraviolet light (e.
• g.
• , sun, tanning beds).
• Strict adherence to sun protection measures (e.
• g.
• , protective clothing, wide-brimmed hats, high-SPF broad-spectrum sunscreen) and avoidance of prolonged sun exposure are imperative throughout the treatment course.
• **Lupus Erythematosus:** Griseofulvin has been reported to precipitate or exacerbate lupus erythematosus-like syndromes or existing systemic lupus erythematosus.
• Patients with a history of lupus or other autoimmune disorders should be treated with extreme caution, and monitoring for signs and symptoms of disease exacerbation is crucial.
• **Alcohol Interaction:** Concomitant consumption of alcohol with griseofulvin can lead to a disulfiram-like reaction (e.
• g.
• , flushing, tachycardia, nausea, vomiting, sweating, headache).
• Patients should be strictly advised to avoid alcohol during treatment and for a period after the last dose.
• **Pregnancy:** Griseofulvin is generally contraindicated in pregnancy due to its demonstrated teratogenic potential (classified as Pregnancy Category X or D by different sources/formulations, indicating a clear risk to the fetus).
• Effective contraception must be used by women of childbearing potential during treatment and for at least one month after the last dose to prevent pregnancy.
• **Drug Interactions:** Due to its enzyme-inducing properties, griseofulvin can significantly reduce the effectiveness of co-administered drugs, most notably oral contraceptives (requiring alternative birth control) and oral anticoagulants (requiring careful monitoring of INR and dose adjustment).
• Barbiturates may also reduce the absorption of griseofulvin, leading to decreased efficacy.